TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27313846

Group type: EXPERIMENTAL
Intervention: DFA-02 (gentamicin 16.8 mg/mL and vancomycin 18.8 mg/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study: 27313852

Group type: EXPERIMENTAL
Intervention: Cheddar cheese high-fat meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vegan-alternative high-fat meal
Number of subjects: 20
Study: 27314177

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 155

Group type: COMPARATOR
Intervention: Non-HIV controls
Number of subjects: 155
Study: 27315132

Group type: EXPERIMENTAL
Intervention: Lacosamide (100mg starting dose, titrated up to 400mg/day)
Number of subjects: 34
Study: 27315764

Group type: EXPERIMENTAL
Intervention: Video-based messaging intervention (10 video vignettes grounded in social learning and social cognitive theories)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Attention control (10 video vignettes focusing on healthy living)
Number of subjects: 1500
Study: 27315835

Group type: EXPERIMENTAL
Intervention: Integrated spasticity management including multiple botulinum toxin A (BoNT-A) injection cycles and concomitant therapies
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Upper Limb Spasticity Index and Goal Attainment Scaling-Evaluation of Outcomes for Upper Limb Spasticity tool
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Concomitant therapy inputs and patient satisfaction with engagement in goal setting
Number of subjects: 1000
Study: 27316444

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: (68)Ga-DOTANOC PET/CT
Number of subjects: 19
Study: 27316465

Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: tiotropium monotherapy
Number of subjects: 0
Study: 27316794

Group type: EXPERIMENTAL
Intervention: Clostridium difficile infection (CDI) cases
Number of subjects: 606058

Group type: EXPERIMENTAL
Intervention: CDI-attributable deaths
Number of subjects: 606058

Group type: EXPERIMENTAL
Intervention: Economic burden of CDI
Number of subjects: 606058
Study: 27316825

Group type: EXPERIMENTAL
Intervention: ProGrip laparoscopic, self-fixating mesh
Number of subjects: 101
Study: 27317257

Group type: EXPERIMENTAL
Intervention: Atypical microorganisms
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Non-respiratory season (week 20 to week 39)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Age <60 years during non-respiratory season
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: CAP acquired in the non-respiratory season
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Age <60 years
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Absence of COPD
Number of subjects: 980
Study: 27317348

Group type: EXPERIMENTAL
Intervention: Follow-up Reactive Hyperemia Index (RHI) measured at 6 and 9 months post-intervention.
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Follow-up RHI as a predictor of ISR.
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Receiver operating-characteristic analysis of F/U RHI.
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Addition of RHI to traditional ISR risk factors.
Number of subjects: 249
Study: 27317471

Group type: COMPARATOR
Intervention: 1 mg midazolam (control phase)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 mg midazolam after pretreatment with 400 mg ketoconazole once daily for 4 days (CYP3A inhibition phase)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2.5 mg midazolam after pretreatment with 600 mg rifampicin once daily for 10 days (CYP3A induction phase)
Number of subjects: 12
Study: 27317630

Group type: EXPERIMENTAL
Intervention: Whole-brain magnetic resonance imaging (MRI) scans including T1-weighted three-dimensional anatomy scan, diffusion tensor imaging, and resting state functional MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental pain testing parameters
Number of subjects: 0
Study: 27317797

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) during acute HIV infection (AHI)
Number of subjects: 234
Study: 27318133

Group type: EXPERIMENTAL
Intervention: (11)C-PBR28 binding in amyloid-positive patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (amyloid-negative)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: (11)C-PBR28 binding in patients with clinical progression
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: (11)C-PBR28 binding
Number of subjects: 22
Study: 27319011

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27319305

Group type: EXPERIMENTAL
Intervention: Opportunistic case finding approach for COPD
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Simple score for detecting COPD
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Weighted score for detecting COPD
Number of subjects: 1743
Study: 27321869

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (opioids, midazolam, anticholinergics)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 152
Study: 27321972

Group type: EXPERIMENTAL
Intervention: Menopausal age (median 50 years)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Men
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Ejection fraction, female sex, ST elevation myocardial infarction
Number of subjects: 426
Study: 27322029

Group type: EXPERIMENTAL
Intervention: Protein intake of 1.4 g protein/kg/d during controlled diet and training, followed by variable test diets providing 0.2-2.8 g·kg-1·d-1 protein after exercise.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Crystalline amino acid mixture based on egg protein with [1-13C]phenylalanine.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Test diets with varying protein amounts post-exercise.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Recommended protein intake compared to RDA and current recommendations for endurance athletes.
Number of subjects: 6
Study: 27322733

Group type: EXPERIMENTAL
Intervention: Actical accelerometer thresholds for sedentary/light activity
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Actical accelerometer thresholds for light/moderate activity
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Actical accelerometer thresholds for moderate/vigorous activity
Number of subjects: 28
Study: 27322859

Group type: EXPERIMENTAL
Intervention: 3D conformal radiotherapy (3D-CRT) APBI, 34-38.5 Gy in 10 fractions over 5 days
Number of subjects: 141
Study: 27322906

Group type: EXPERIMENTAL
Intervention: Calcichew D3 500/400
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Calcichew D3 500/800
Number of subjects: 276

Group type: COMPARATOR
Intervention: Adcal-D3
Number of subjects: 276

Group type: COMPARATOR
Intervention: Kalcipos-D
Number of subjects: 276
Study: 27323698

Group type: EXPERIMENTAL
Intervention: Statistical definitions of individual benefit of medical or behavioral treatment using generalized linear mixed-effects models.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized linear mixed-effects models applied to clinical trial data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from the Sequenced Treatment Alternatives to Relieve Depression clinical trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from a clinical trial of respiratory treatments.
Number of subjects: 0
Study: 27324108

Group type: COMPARATOR
Intervention: Olaparib
Number of subjects: 0
Study: 27324671

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27324719

Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)) for up to 2.5 years
Number of subjects: 300
Study: 27324768

Group type: EXPERIMENTAL
Intervention: Linezolid (standard dosing)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Simulated patients (n = 67,000)
Number of subjects: 52
Study: 27325219

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for multiple attacks
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for pancreas divisum
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for sphincter of Oddi dysfunction (SOD)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Follow-up after a single idiopathic attack with negative EUS
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 201
Study: 27325286

Group type: EXPERIMENTAL
Intervention: [(11)C]5-HTP PET
Number of subjects: 8
Study: 27325334

Group type: EXPERIMENTAL
Intervention: BRCA1-like profile by array comparative genomic hybridization (aCGH) testing
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: BRCA1-like profile by multiplex ligation-dependent probe amplification (MLPA) testing
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Strategy 1 followed by X-inactive specific transcript gene (XIST) and tumor suppressor p53 binding protein (53BP1) testing
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Strategy 2 followed by XIST and 53BP1 testing
Number of subjects: 3000
Study: 27325409

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (32-34 °C) for 24 hours with propofol sedation
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 270
Study: 27325604

Group type: EXPERIMENTAL
Intervention: High-dose oral vitamin D
Number of subjects: 0
Study: 27325685

Group type: EXPERIMENTAL
Intervention: Lapatinib plus Capecitabine (Lapatinib 1,250 mg daily and Capecitabine 1,000 mg/m² twice daily for 14 days)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lapatinib plus Capecitabine
Number of subjects: 68
Study: 27325856

Group type: COMPARATOR
Intervention: MMR normal group
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Epigenetic MMR defects
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Probable MMR mutation cases
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: MMR defects in EECs
Number of subjects: 1024
Study: 27325859

Group type: EXPERIMENTAL
Intervention: Hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) administered at a planned dose of 50.4 Gy in 28 fractions.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hemithoracic IMPRINT
Number of subjects: 45
Study: 27326168

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 27326241

Group type: EXPERIMENTAL
Intervention: Exercise ECG
Number of subjects: 0
Study: 27326819

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) and resistance training (RT) for 1 year
Number of subjects: 31
Study: 27326862

Group type: EXPERIMENTAL
Intervention: Insulin analogue regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human insulin regimen
Number of subjects: 0
Study: 27328169

Group type: EXPERIMENTAL
Intervention: Telemedicine with nonmydriatic cameras
Number of subjects: 424
Study: 27328699

Group type: EXPERIMENTAL
Intervention: hsCRP >3.0 mg/L
Number of subjects: 3044

Group type: COMPARATOR
Intervention: hsCRP <1 mg/L
Number of subjects: 3044
Study: 27328702

Group type: EXPERIMENTAL
Intervention: Stroke emergency mobile (specialized stroke ambulance)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Conventional emergency medical service
Number of subjects: 430
Study: 27328985

Group type: EXPERIMENTAL
Intervention: EUS-guided gallbladder drainage (EUS-GBD)
Number of subjects: 35
Study: 27329247

Group type: EXPERIMENTAL
Intervention: PF-03446962 7 mg/kg intravenously biweekly
Number of subjects: 24
Study: 27329447

Group type: EXPERIMENTAL
Intervention: Men in upright position
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Men in supine position
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Heart rate variability in men
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Subgroup of men and postmenopausal women (n=76, aged >55 years)
Number of subjects: 334
Study: 27329686

Group type: EXPERIMENTAL
Intervention: Social-emotional content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social content
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Object stimuli
Number of subjects: 0
Study: 27330001

Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain (prophylactic regimen)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain (on-demand regimen)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: rVIII-SingleChain (surgical prophylaxis)
Number of subjects: 175
Study: 27330024

Group type: EXPERIMENTAL
Intervention: Group 2 (≥2 mm RTT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 1 (<2 mm RTT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 27330166

Group type: EXPERIMENTAL
Intervention: ACPA positive patients
Number of subjects: 1996

Group type: COMPARATOR
Intervention: ACPA negative patients
Number of subjects: 1996
Study: 27330809

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab
Number of subjects: 1
Study: 27330808

Group type: EXPERIMENTAL
Intervention: Single dose denileukin diftitox (18 mcg/kg) prior to vaccination
Number of subjects: 17

Group type: COMPARATOR
Intervention: 4-peptide vaccine (Melan-A, gp100, MAGE3 and NA17 with GM-CSF emulsified in Montanide) alone
Number of subjects: 17
Study: 27331367

Group type: EXPERIMENTAL
Intervention: Inhalation of LPS via MB2 nebulizer (3.2 μm)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inhalation of LPS via Pari nebulizer (7.9 μm)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Inhalation of LPS via Microcirrus nebulizer (2.0 μm)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inhalation of large droplets of LPS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response
Number of subjects: 3
Study: 27331585

Group type: EXPERIMENTAL
Intervention: ShangRing circumcision (VMMC)
Number of subjects: 1149
Study: 27332703

Group type: EXPERIMENTAL
Intervention: LINKAGE intervention (6 group-based, manual-guided sessions on patient engagement and health information technology)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: LINKAGE intervention
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: LINKAGE intervention (full components)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 503
Study: 27332992

Group type: EXPERIMENTAL
Intervention: PAD group
Number of subjects: 742

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 742
Study: 27333938

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (self-regulated exercise)
Number of subjects: 50
Study: 27333947

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) administered as a single 600 mg dose followed by multiple doses to steady-state.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Efavirenz concentrations exceeding 0.4 μg/mL.
Number of subjects: 57
Study: 27334213

Group type: EXPERIMENTAL
Intervention: Percutaneous core needle biopsy (PNB) of axillary sentinel lymph nodes (SLNs)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Preincision axillary ultrasound
Number of subjects: 25
Study: 27334557

Group type: EXPERIMENTAL
Intervention: Maximal heart rate (HR) in girls
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Unsupervised physical activity in girls
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Lean body mass in girls
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Errors in static balance test in girls
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Unsupervised physical activity in boys
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Resting HR in boys
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Hand grip strength in boys
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Errors in static balance test in boys
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Organized football in boys
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Unsupervised trampoline jumping in boys
Number of subjects: 339
Study: 27334671

Group type: EXPERIMENTAL
Intervention: Bisoprolol/amlodipine FDC 5/5 mg OD
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bisoprolol monotherapy failure
Number of subjects: 200

Group type: COMPARATOR
Intervention: Amlodipine monotherapy failure
Number of subjects: 200
Study: 27335027

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks) in combination with chemotherapy
Number of subjects: 314
Study: 27335060

Group type: EXPERIMENTAL
Intervention: Children with neonatal AKI (AKI-C)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control children without AKI
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Entire cohort (both groups)
Number of subjects: 74
Study: 27335651

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Seated position
Number of subjects: 72
Study: 27335883

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (5 mgs/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 27336356

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone administration
Number of subjects: 38
Study: 27336786

Group type: EXPERIMENTAL
Intervention: TIIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATIIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study: 27337418

Group type: EXPERIMENTAL
Intervention: Nocturnal wakefulness at 4:00 am
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Polysomnographically documented sleep disruption
Number of subjects: 65
Study: 27338133

Group type: EXPERIMENTAL
Intervention: Low-normal TSH levels (≤2.5 mU/L)
Number of subjects: 132

Group type: COMPARATOR
Intervention: High-normal TSH levels (>2.5 mU/L)
Number of subjects: 132
Study: 27338143

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (etanercept)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PsoA patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TWEAK-binding IgG autoantibodies
Number of subjects: 70
Study: 27338191

Group type: EXPERIMENTAL
Intervention: Interval training, details on dosage and duration not available
Number of subjects: 0
Study: 27338778

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 15132

Group type: COMPARATOR
Intervention: Adalimumab-plus-methotrexate
Number of subjects: 15132

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 15132

Group type: EXPERIMENTAL
Intervention: Adalimumab (in pregnant women)
Number of subjects: 15132
Study: 27338994

Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pedometer + Goal Prompt
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pedometer + Goal Prompt + Theory-informed Texts
Number of subjects: 160

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 160
Study: 27339489

Group type: EXPERIMENTAL
Intervention: Percutaneous direct annuloplasty
Number of subjects: 71
Study: 27339555

Group type: EXPERIMENTAL
Intervention: Cervical spine MRI assessment
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cervical cord compression
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Surgical complications
Number of subjects: 213
Study: 27339614

Group type: EXPERIMENTAL
Intervention: Lambda-IFN/RBV/DCV for 12 weeks (cohort A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Lambda-IFN/RBV/DCV for 12 weeks followed by Lambda-IFN/RBV for an additional 12 weeks (cohort B)
Number of subjects: 51
Study: 27339787

Group type: EXPERIMENTAL
Intervention: Lung Clearance Index (LCI)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Maximal Mid-Expiratory Flow (MMEF)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Changes in LCI during bronchiectasis exacerbations (BEs)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Changes in MMEF% predicted during bronchiectasis exacerbations (BEs)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses in mild, moderate and severe bronchiectasis
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: MMEF% predicted
Number of subjects: 110
Study: 27340399

Group type: EXPERIMENTAL
Intervention: Pigtail catheter insertion
Number of subjects: 60
Study: 27340749

Group type: EXPERIMENTAL
Intervention: Olipudase alfa (recombinant human ASM) administered every 2 weeks for 26 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Olipudase alfa (recombinant human ASM)
Number of subjects: 5
Study: 27342239

Group type: EXPERIMENTAL
Intervention: Idarubicin 5 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Idarubicin 10 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Idarubicin 15 mg
Number of subjects: 21
Study: 27342412

Group type: EXPERIMENTAL
Intervention: Breakthrough cancer pain (BTP)
Number of subjects: 978

Group type: COMPARATOR
Intervention: No BTP
Number of subjects: 978
Study: 27342580

Group type: EXPERIMENTAL
Intervention: Urinary TIMP-2 and IGFBP7 biomarker test
Number of subjects: 0
Study: 27342743

Group type: EXPERIMENTAL
Intervention: Previous use of hormonal treatment for endometriosis
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Previous surgery for endometriosis
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Living or working in a city or by a busy area
Number of subjects: 1008
Study: 27342748

Group type: EXPERIMENTAL
Intervention: Omegaven (intravenous infusion of omega-3 polyunsaturated fatty acids)
Number of subjects: 21
Study: 27342758

Group type: COMPARATOR
Intervention: Intravenously administered IGIV-C (200-600 mg/kg per infusion every 3-4 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneously administered IGIV-C (calculated using a conversion factor of 1.37 times the prior IV dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenously administered IGIV-C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneously administered IGIV-C
Number of subjects: 12
Study: 27343060

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention for heart failure patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 0
Study: 27343748

Group type: EXPERIMENTAL
Intervention: DNG/EV
Number of subjects: 50203

Group type: COMPARATOR
Intervention: oCOC (including LNG)
Number of subjects: 50203
Study: 27345129

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 0